Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01077258
First received: February 25, 2010
Last updated: April 9, 2014
Last verified: April 2014
Results First Received: February 28, 2014  
Study Type: Observational
Study Design: Observational Model: Case-Only;   Time Perspective: Prospective
Condition: Rheumatoid Arthritis

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Rheumatoid Arthritis Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed for up to 24 months.

Participant Flow:   Overall Study
    Rheumatoid Arthritis  
STARTED     4208  
COMPLETED     1640  
NOT COMPLETED     2568  
Lost to Follow-up                 1390  
Adverse drug reaction                 218  
Lack of Efficacy                 663  
Clinical remission                 37  
Other reasons                 260  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Rheumatoid Arthritis Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed for up to 24 months.

Baseline Measures
    Rheumatoid Arthritis  
Number of Participants  
[units: participants]
  4208  
Age [1]
[units: years]
Mean ± Standard Deviation
  54.6  ± 13.2  
Gender [2]
[units: participants]
 
Female     3199  
Male     958  
Region of Enrollment  
[units: participants]
 
Germany     4208  
[1] Age data was available for 4147 participants
[2] Gender data available for 4157 participants



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in Disease Activity Score (DAS) 28   [ Time Frame: Baseline and Months 3, 6, 9, 12, 18, and 24 ]

2.  Primary:   Percentage of Participants in DAS28 Remission   [ Time Frame: Months 3, 6, 9, 12, 18, and 24 ]

3.  Secondary:   Percentage of Participants With a Significant Therapeutic Response   [ Time Frame: Baseline and Months 3, 6, 9, 12, 18, and 24 ]

4.  Secondary:   Percentage of Participants With Low, Moderate and High Disease Activity   [ Time Frame: Baseline and Months 3, 6, 9, 12, 18, and 24 ]

5.  Secondary:   Erythrocyte Sedimentation Rate (ESR) Over Time   [ Time Frame: Baseline and Months 3, 6, 9, 12, 18, and 24 ]

6.  Secondary:   C-Reactive Protein (CRP) Levels Over Time   [ Time Frame: Baseline and Months 3, 6, 9, 12, 18, and 24 ]

7.  Secondary:   Tender Joint Count (TJC) Over Time   [ Time Frame: Baseline and Months 3, 6, 9, 12, 18, and 24 ]

8.  Secondary:   Swollen Joint Count (SJC) Over Time   [ Time Frame: Baseline and Months 3, 6, 9, 12, 18, and 24 ]

9.  Secondary:   Hannover Functional Questionnaire (FFbH) Over Time   [ Time Frame: Baseline and Months 3, 6, 9, 12, 18, and 24 ]

10.  Secondary:   Patients Global Assessment of Disease Activity Over Time   [ Time Frame: Baseline and Months 3, 6, 9, 12, 18 and 24 ]

11.  Secondary:   Participants Assessment of Fatigue Over Time   [ Time Frame: Baseline and Month 3, 6, 9, 12, 18, and 24 ]

12.  Secondary:   Participants Assessment of Pain Over Time   [ Time Frame: Baseline and Months 3, 6, 9, 12, 18, and 24 ]

13.  Secondary:   Percentage of Participants With Impairment in Daily Activities   [ Time Frame: Baseline and Months 3, 6, 9, 18, and 24 ]

14.  Secondary:   Number of Days Missed From Work Due to Rheumatoid Arthritis   [ Time Frame: Baseline and Months 6, 12, 18, and 24 ]

15.  Secondary:   Percentage of Participants With In-patient Hospitalization   [ Time Frame: Month 6, 12, 18, and 24 ]

16.  Secondary:   Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication   [ Time Frame: Baseline and Months 3, 6, 9, 12, 18, and 24 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Global Medical Services
Organization: AbbVie (prior sponsor, Abbott)
phone: 800-633-9110


No publications provided


Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier: NCT01077258     History of Changes
Other Study ID Numbers: P10-448
Study First Received: February 25, 2010
Results First Received: February 28, 2014
Last Updated: April 9, 2014
Health Authority: Germany: Paul-Ehrlich-Institut